About us
The independent Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, IQWiG) examines the benefits and harms of medical interventions for patients.
Projects
Participation
Events
Press
Contact
Breadcrumbs
Last updated 05.12.2022
Project no.: A19-10
Commission: Commission awarded on 30.01.2019 by the Federal Joint Committee (G-BA).
Report type: Report
Status: Commission completed
Department/Division: Drug Assessment
Application field: Muscles, bones and joints
Final report: Benefit assessment of bisphosphonates, teriparatide and denosumab for the treatment of postmenopausal osteoporosis
published on Dec 5, 2022
Documentation of comments on the preliminary report: Benefit assessment of bisphosphonates, teriparatide and denosumab for the treatment of postmenopausal osteoporosis
Preliminary report: Benefit assessment of bisphosphonates, teriparatide and denosumab for the treatment of postmenopausal osteoporosis
published on Jun 2, 2022
Documentation of comments on the report plan: Benefit assessment of bisphosphonates, teriparatide and denosumab for the treatment of postmenopausal osteoporosis
Report plan: Benefit assessment of bisphosphonates, teriparatide and denosumab for the treatment of postmenopausal osteoporosis
published on Dec 10, 2019
Press contact
+49 221 356850
presse@iqwig.de
Info Service
Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.
Contact form
Questions about commissions, publications and press releases can be sent to us via this form.
